TAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as Idiopathic Multicentric Castleman Disease-TAFRO or a Distinct Disease Entity?

Turk J Haematol · 2025 · PMC11869139 · PMID 39935291

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Long-term outcomes, as reflected by the 3-year estimated PFS and OS rates, showed a trend favoring TAFRO-w/o-iMCD patients, though the differences were not statistically significant ( Figure 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.